CAMK2G and depressive symptom measurement: Moreover, inhibiting CaMKII phosphorylation via microinjection of KN‐93—a CaMKII activation inhibitor—into the mPFC alleviated depression‐like behavior and cognitive deficits, but not anxiety‐like behavior.